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Abstract
Purpose: For 30 years nature has provided a plethora of natural products with potential meaningful anti-cancer
activity. Fusarochromanone (FC101a) is a small molecule fungal metabolite exhibiting potent in-vitro growth inhibitory
effects and is capable of inducing apoptosis, suppressing angiogenesis and tumorigenesis, and inhibiting endothelial
cell growth in multiple cancer cell lines. Despite all we know regarding FC101a, the mechanism of action and molecular
target(s) of this compound have remained an enigma. Furthermore, modest in-vivo activity has been documented and
requires addressing.
Method: Early stage pharmacokinetics (PK) assessment is vital to successful drug development. Herein, we
aimed to use in-silico assays to i) characterize an in-depth ADMET profile of FC101a and ii) to probe for possible
therapeutic targets. Two-dimensional SDF files of FC101a and 13 analogs were introduced into ADMET Predictor
Version 7.1 that parses the structures in order to calculate molecular descriptors, which are used to estimate
ADMET properties. Calculated ADMET values were analyzed and subjected to multiple drug-like indices, delivering
a PK profile of each analog. To probe for possible targets, a total of 49 proteins were introduced into SYBYL-X
Version 2.0 platform and the deepest binding pocket of each protein was virtually docked with parent compound,
FC101a; with the negative control, FC101b; and with the model compound, kynurenine.
Results: Each analog showed promising ADMET qualities, although FC101 Oxazole was identified as the most
optimized analog. Despite FC101a having a desirable ADME and toxicity profile, areas of concern were identified
and must be addressed in-vitro. These include potential mutagenic properties and estrogen receptor toxicity. We
provide potential avenues medicinal chemists could use to achieve higher effective permeation, higher blood
brain barrier (BBB) penetration, and higher aqueous solubility in FC101a. Molecular docking assays revealed
procaspase-8 - cFLIP(L) complex as a potential biological target and led to proposed mechanisms of action by
which FC101a facilitates procaspase-8 heterodimerization, thereby increasing proteolytic activity and up regulating
extrinsic apoptosis.
Conclusion: Our data revealed both potential mechanisms of action and a promising ADMET profile of FC101a.
These attributes render FC101a a promising lead candidate for development into a low toxic anti-cancer agent
effective against a broad range of cancers.
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Background
For 30 years nature has provided scientists a plethora of
natural products with potential meaningful anti-cancer
activity. Since 1940, approximately 175 small molecules
have been approved as anti-cancer agents; of these,
48.6 % were a natural product or derivative (Newman
and Cragg 2012). Fusarochromanone (FC101a) is a small
molecule fungal metabolite exhibiting potent in-vitro
growth inhibitory effects in 35 of 58 human cancer lines
through a novel mode of action (Mahdavian et al.
2014a). FC101a demonstrates a multi-focal approach to
inhibiting cancer growth that includes induction of
apoptosis, suppression of angiogenesis and tumorigen-
esis, and direct inhibition of endothelial cell growth,
evident by MTT cell viability assays, FACS analysis, and
western blotting (Mahdavian et al. 2014a). Due to these
characteristics, we believe FC101a is a promising lead
candidate for an anti-cancer agent effective against a
broad range of cancers.
Although FC101a anti-cancer activity has been well
documented, its biological target(s) and mechanism of
action have remained enigmatic; according to a NCI
COMPARE study, its mode of action is novel when
compared to a database including 50,000 compounds
(Mahdavian et al. 2014a). Furthermore, diminished in-vivo
potency remains an obstacle and requires addressing- the
large disparity between levels of activity in-vivo and in-
vitro suggests the molecule requires structural modifica-
tions to maximize its activity. Two questions become
clear: how is in-vivo potency diminished, and how can we
improve in-vivo potency? The use of in-silico assays is key
to answering both questions and to uncovering the bio-
logical target(s) of FC101a. Although FC101a ADMET
properties exclusive to Lipinski’s Rule of 5 (RO5) have
been recorded, a more robust ADMET profile was un-
available until now.
The four objectives of this study were: (1) to select
optimized FC101a analogs for synthesis, (2) to
characterize an in-depth ADMET profile of FC101a, (3)
to discover potential avenues medicinal chemists could
use to optimize FC101a, and (4) to search for the thera-
peutic target(s) of FC101a. Herein, we use multiple
state-of-the-art computer modeling software programs
and open-source platforms to perform in-silico assays
on FC101a and multiple lead analogs; thereby generat-
ing an in-depth PK profile of FC101a and structural
analogs (SA). In-silico fishing techniques, which require
a pool of potential targets, were applied to search for
the unknown biological target(s) of FC101a. Potential
targets were selected for molecular docking based on
previously performed cell viability and western blot
assays, and availability of unambiguous crystal struc-
tures. FC101a increases caspase-3 and PARP cleavage,
as well as caspase-8 activity (Fig. 1). Furthermore, Fig. 2
Fig. 1 Western blot with antibodies for caspase proteins involved in
apoptosis. MDA-MB-231 cells, grown in 6-well plates, were treated
with FC101 (0–1 μM) for 24 h, followed by western blotting with
antibodies to cleaved caspase-3, cleaved caspase 8, and cleaved
PARP. Upregulation of CC8, CC3, and cleaved PARP indicate caspase
activation and apoptosis upregulation in a concentration-dependent
manner. β-Tubulin was used as house keeping protein
Fig. 2 Western blot with antibodies for pro and anti apoptotic
factors. MDA-MB-231 cells, grown in 6-well plates, were treated with
FC101 (0–1 μM) for 24 h, followed by western blotting with antibodies
to anti-apoptotic proteins (Bcl-2, Bcl-XL, Mcl-1) and pro-apoptotic
proteins (BAD, BAK, BAX). Protein expression remains unchanged.
β-Tubulin was used as house keeping protein
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illustrates that FC101a does not affect anti-apoptotic
proteins (Bcl-2, Bcl-XL, Mcl-1) or pro-apoptotic
proteins (BAD, BAK, BAX); further attesting that
FC101a induces apoptotic cascades by means of an
extrinsic mechanism involving caspase-8 (Mahdavian et
al. 2014a). Therefore proteins upstream of caspase-3,
caspase-8, and PARP were selected as potential targets,
but only if unambiguous crystal structures were avail-
able through RCSB- in total 49 proteins were selected.
Methods
ADMET predictor calculations
ADMET values for FC101a, 12 structural analogs, and
one model compound were predicted using Simulations-
Plus ADMET Predictor Version 7.1 on a Windows XP
operating system. ADMET Predictor software was de-
signed using artificial neural network ensemble (ANNE)
models trained with well-defined drugs, and was chosen
for it’s high prediction accuracy, and descriptor sensitivity
analysis capabilities. An additional Excel file displays all
predicted properties for each structure, including an out-
of-scope indicator column for each model [see Additional
file 1].
Chemical structure of FC101a (Fig. 3) and structural
analogs were sketched in three-dimensional space using
Tripos SYBYL-X Version 2.1 sketch mode installed on a
64GB Mac, and molecules were saved individually in
MOL2 format. ADMET Predictor is unable to optimize
structures; therefore energy minimization was performed
in SYBYL-X prior to exporting structures into ADMET
Predictor. Structures were exported into a single 2D
SDF format named Jupiter04_multi21_2Dsdf.sdf and in-
troduced into Simulations-Plus ADMET Predictor- see
Additional file 2 for original .sdf file. Simulations-Plus’s
Physiochemical and Biopharmaceutical Module and
Toxicity Module were applied to calculate 341 molecu-
lar descriptors. Next, the software automatically uses
descriptors as inputs to independent mathematical models
to estimate a range of ADMET values at relevant pH 2.5
and pH 7.4. A rank ordered list of FC101a and 13 SA was
generated using S + Absn_Risk and S + ADMET_Risk.
Each violation contributes up to one vote “point” to the
score, where points represent a liability towards oral ab-
sorption and/or toxicity in humans.
Specific ADMET values of interest included predicted
logD (S + logD), predicted aqueous solubility (S + Sw),
logS (value predicted by OSIRIS Data Warrior Version
4.1.1), predicted effective permeability (S + Peff ), predicted
apparent permeability (S +MDCK), and manually calcu-
lated Fsp3 to characterize absorption and solubility of
FC101a hits. When evaluating the distribution of FC101a
hits, three values were considered: percent unbound to
plasma proteins (S + PrUnbnd, aka fup) blood-to-plasma
concentration ratio (S + RBP), and volume of distribution
(S + Vd). We used ADMET Predictor to both qualify and
quantify the likelihood of penetrating the blood brain bar-
rier (BBB), a requirement of all neurotherapeutic agents.
A binary classifier (High/Low) and a regression model
estimating the decimal logarithm of rat brain–blood
partition coefficient (log [brain/blood]) were used. To
determine excretion routes, FC101a hits were grouped
by charge; predicted logD, molecular weight (MW), and
predicted fup, which were plotted in three-dimensional
space and results were subjected to a known in-silico
classification system proposed by Kusama et al. (2010).
To assess for FC101a related toxicity risk, we considered
predicted LD50 and TD50 values, two robust toxicity
filters, and S + Pgp_Substrate model to qualify the likeli-
hood of binding to transporter permeability-glycoprotein
(P-gp). Additionally, a specificity matrix was generated to
further assess the risk for potential adverse side effects
due to target specificity (discussed below). Data were
exported to Excel for analysis. Attention was drawn to
areas of potential risk associated with oral BA and/or
toxicity.
To suggest next stage optimization, relationships be-
tween certain model outputs and molecular descriptors
were defined using Descriptor Sensitivity Analysis (DSA)
tool. DSA determines the partial derivative of a model
(i.e., S + logD, S + SW) in response to a fixed molecular
descriptor. Models influencing sub-par ADMET proper-
ties of FC101a were of particular interest, and descrip-
tors most influencing said models were examined using
the DSA tool. A flowchart depicting our methodologies
is illustrated in Fig. 4.
ADMET predictor software validation
The use of ADMET prediction software has become well
recognize over recent years for its role in early stage
drug discovery and development. Moreover, predictive
properties increase in usefulness when researchers
Fig. 3 Structure of Fusarochromanone (FC101a). Two-dimensional
structure of the parent compound Fusarochromanone (FC101a
or FC101)
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consider the accuracy of the prediction model. In an at-
tempt to estimate prediction accuracy, each predicted
value of each drug of interest was assed to qualitatively de-
termine if it’s calculated end-points fell within the applic-
ability domain (AD) of the model – a default feature of
Simulations-Plus ADMET Predictor. Values falling outside
the AD were ignored, thus ensuring our accepted data
were derived from predictive models designed with com-
pounds occupying the same chemical space as our drugs
of interest. Additional file 1 indicates out of scope values
and are highlighted in magenta.
Statistical measures of the performance of linear re-
gression models and binary classification models were
checked using external test sets to further examine the
overall reliability of each predictive model. Each model
of interest was tested by Simulations-Plus using external
test sets of drugs not included in the training process. R2
values between observed and predicted ADMET proper-
ties of interest, and sensitivity/specificity for binary tests
were checked for models relevant to this study. Data pro-
vided by Simulations-Plus are summarized in Additional
file 3, and readers should refer to his file when interested
in the prediction accuracy of any model discussed within
this paper.
Determining docking protocol and active range
Tripos’ SYBYL-X Version 2.1 was chosen to conduct
molecular docking experiments due to it’s ability to
execute multiple scoring functions at once while provid-
ing individual scores and overall consensus ranking. Mo-
lecular docking protocol and accurate consensus scoring
parameters were determined from a series of dockings
performed between a well-defined model compound and
it’s known biological target. Kynurenine, a naturally oc-
curring metabolite and biological substrate exhibiting
structural similarity with FC101a, was selected as the
model compound. Searching SciFinder structural simi-
larity database using SMILES Notation of the following
FC101a structure: C1(=C2C(=CC = C1C(CC(CO)N) =
O)OC(CC2 =O)(C)C)N, returned kynurenine as the only
naturally occurring metabolite (Furmanski dissertation,
Unpublished Observations). The two molecules share a
similarly placed o-carbonyl and aliphatic amino group
along its side chain, as well as an anilinic aromatic ring.
In order to i) optimize SYBYL-X parameters for FC101a
and ii) determine a range of activity, multiple dockings
between the model compound, kynurenine, and it’s known
biological target, human kynurenine aminotransferase II
(PDB IDs 2R2N and 2QLR), were first carried out. A flow-
chart depicting our methodology covered below is illus-
trated in Fig. 5.
Ten different settings were applied each time and
those parameters ultimately selected as default placed
kynurenine in the top binding position with a C Score ≥ 4,
shown in Table 1. These parameters include GeomX set-
ting, water molecule extraction, charging of all termini
Fig. 4 Methodology flowchart for generating ADMET profile of FC101a. Flowchart depicts the steps taken to procure predicted ADMET values
and to determine the ADMET profile of FC101a
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including gaps, adding hydrogens via H-bonding function,
rigid protein model, and eliminating proteins with a C
Score < 4. The overall structure was minimized with
charges set to MMFS94 and MMfs94s force field. Poten-
tial binding sites in the protein structures were identified
by generating a protomol using one of three methods;
Multi-Channel Surface (MCS) mode, Automatic mode
when MCS mode was unavailable, and Ligand extraction
mode when interested in a specific binding pocket bound
by a co-crystallized ligand. A probe radius of 1.4 Å2 was
used and threshold was set to .50 and bloat to 1 in order
to increase the size and depth of the searchable cavity for
a binding site. The top two ligand poses were considered
in order to account for flexibility in the binding pocket.
Results from both dockings were exported to Excel for
analysis and used to determine parameters for future
dockings with FC101a. Although multiple scoring func-
tions were tabulated, Total Score (default scoring function
used by Surflex dock to generate and rank poses) and C
Score (consensus scoring function that combines multiple
scoring functions to rank the affinity of a ligand to the
active site) were given priority in analysis- targets will be
ranked first by C Score and then Total Score. It should be
noted that Total Score is not part of the C Score consen-
sus. This method could be a useful approach for re-
searchers who need to generate appropriate parameters
for comparable tasks, and indeed others have utilized
similar approaches.
Ligands and protein preparation
Protein-ligand dockings were carried out on the crystal
structure of 49 potential biological. Protein prepar-
ation took place prior to docking and each structure
was prepared using the Atom Expression View tool
and Structure Preparation tool of SYBYL-X software
package. Crystal structures of proteins were retrieved
from rcsb.org through SYBYL-X interface followed by
preparation and staged minimization as described in
the above section. Each protein was exported and
saved in the following format: pdbPDBID_P.mol2,
where “_P” lets the researcher know this protein has
been prepared.
Fig. 5 Methodology flowchart for molecular docking portion of study. Flowchart depicts the steps taken to determined a docking protocol using
a model compound, kynurenine
Table 1 Control molecular dockings between hKATII and
kynurenine
Protein Ligand Protomol Total Score C Score
2R2N pdb2r2n_ligand Ligand extraction 8.053 5
2R2N Kynurenine_z Ligand extraction 6.1745 4
2R2N FC101b_inactive Ligand extraction 7.3148 2
2R2N FC101a_04 Ligand extraction 6.5068 1
2QLR pdb2r2n_ligand Automatic mode 5.1002 5
2QLR Kynurenine_z Automatic mode 4.3048 5
2QLR FC101b_inactive Automatic mode 6.2713 4
2QLR FC101a_04 Automatic mode 5.2248 2
These dockings were used to determine the molecular docking protocol
applied to FC101a and proteins of interest. Kynurenine, represented by
pdb2r2n_ligand and Kynurenine_z, are the natural substrates of 2R2N and
2QLR; all four dockings received a C Score ≥ 4, evidence to the validity of C
Score in accurately ranking compounds of similar structure to kynurenine
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The structure of FC101a and both reference compounds
were prepared using SYBYL-X Sketch Mode. FC101a
was saved as FC101_a_04.mol2; FC101b was saved as
FC101b_inactive.mol2; and kynurenine was saved as
kynurenine_z.mol2. FC101b, the anti anti-cancer analog
served as the negative control. This set of small mole-
cules was saved collectively as leadset4_multi3.mol2 and
underwent energy minimization using default settings.
Molecular docking of ligands to potential FC101a targets
We created a docking setup file for each protein of inter-
est. Protomols were generated using MCS mode and
surface one was selected each time; if no channels were
present, automatic mode was selected. Ligand source
was set to MOL2 and leadset4_multi3.mol2 was used as
the ligand source file and the job name format was:
Dockingrun_pdbID_ligand source_000. Additional file 4
Table 2 Approved drugs and corresponding targets used to generate 2D specificity matrix
No. Biological target Corresponding drug
1 Lymphocyte function-associated antigen LFA-1 (CD11A) Lovastatin
2 Human Coagulation Factor 5-dimethyl amino 1-naphthalene sulfonic acid
3 Retinol-Binding Protein Fenretinide
4 Human cardiac troponin C Bepridil
5 DNA {d(CGCGAATTCGCG)} Propamidine (TNT)
6 Progesterone receptor Mometasone furoate
7 Platelet receptor for fibrinogen Tirofiban
8 Human phosphodiesterase 4B Roflumilast
9 Cyclooxygenase-2 enzyme Indomethacin
10 Estrogen receptor 4-hydroxytamoxifen
11 ADP/ATP Translocase-1 Carboxyatractyloside
Drugs and their corresponding targets are numbered from top to bottom in same order as presented in specificity matrix. Each drug has been FDA approved and
is currently on the market
Fig. 6 Bar graph summarizing properties of FC101a and SA in relation to Lipinski’s RO5. Bar graphs displays the distribution of properties related
to Lipinski’s RO5. RO5 is perhaps the most used computational filter in drug candidate screening. Only 8.3 % of drugs within the focused WDI
violated more than one of Lipinski’s rules (Lipinski et al. 1997). a MW, b S+ logP, c HBD, d HBA. All properties meet Lipinski’s RO5, denoted by the
red line. FC101a is highlighted in blue
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details the precise protocol for each protein. Upon com-
pletion, all molecules were selected and results were
saved in the SYBYL-X home directory. The top two
poses were selected and output format was set to
spreadsheet. Data was exported as TSV format and saved
in Excel for later analysis. Two circumstances resulted in
the elimination of a protein from being considered: (i) a
C Score < 4, and (ii) a higher affinity with the negative
control, FC101b. Each docking required approximately
15 min.
Specificity matrix generated using SYBYL-X
A specificity matrix was generated to examine FC101a
specificity using targets that span the class of all known
therapeutic targets, a method first performed by Shaikh
et al. (2007). Eleven commercially available drugs were
sketched in SYBYL-X sketch mode and saved as
MOL2 files. We moved each drug into a collective file
also containing FC101a- the file was named: drugma-
trix_file_multi12.mol2. Molecular structures were con-
firmed by comparison to pubchem.org structures of
the same active molecule. Crystal structures of the
therapeutic target of each drug were then retrieved
from rcsb.org and prepared as described in previous
sections. All RCSB targets were bound to their corre-
sponding drug; therefore, ligand extraction mode was
used to extract the ligand and to generate a respective
protomol. Drugs and their corresponding target, il-
lustrated in Table 2, were selected from a data set
published by Shaikh et al. (2007). We virtually docked the
native ligand back into the protein to generate a threshold
representing strong affinity. Each prepared protein was
docked with drugmatrix_file_multi12.mol2, using MCS
mode to generate protomols. Dockings were performed
individually and data was saved in the manner as
previously described. Drugs were aligned along the Y-
axis and targets along the X-axis, ensuring row 1 (drug)
matched column 1 (said drug’s therapeutic target). If
drugs are specific to their target, then high affinity
binding should only occur along a diagonal line. An
additional file details the above protocol [see Additional
file 5] and Fig. 4 provides a methodology flowchart of
our full docking strategy.
Fig. 7 Selective criteria for drugs with rat oral BA > 20-40 %. a Scatter plot, rotatable bonds vs PSA, of FC101a hits. Each optimized hit is within
the range of drugs demonstrating oral BA > 20-40 % in rat models- indicated by the shaded region. b Scatter plot, rotatable bonds VS HBD+ HBA
count. Regions shaded red indicate oral rat BA > 20-40 %. FC101 Phos is the only SA outside of shaded region
Table 3 Ranking of FC101a structural analogs by S + Absn_Risk
and S + ADMET_Risk filters
Analog S + Absn_Risk S + ADMET_Risk
FC101 Oxazolea 0 0
FC101b 0 0
FC101 Imidazole 0 0.06




FC101 Acetonide R 0 1
FC101 Dehyroxyl 0 1




FC101 Phos 3.5 3.5
Compounds are ranked based on S + ADMET_Risk scores with lower scores
representing less potential liability. S + Absn_Risk ≥ 3.5 for ~10 % of the
focused World Drug Index (WDI), and if we accept 3.5 as a cut-off to designate
compounds at risk of poor oral bioavailability, then FC101a Phos is the only SA
to exceed the cut-off. S + ADMET_Risk is greater than 6.5 for ~10 % of the focused
WDI, and if we accept 6.5 as a cut-off to eliminate high-risk compounds, then we’re
unable to eliminate any SA from our library. aHighlights FC101 Oxazole, the only
compound receiving a 0 score from both filters
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Results and discussion
Predicting oral BA and selecting the most optimized
structural analogs
In order to accurately select the most optimized FC101a
analogs, four drug-like indices were utilized for compari-
son; Lipinski’s RO5, Veber’s selective criteria for oral bio-
available drugs, and two computational filters designed by
Simulations-Plus, S + Absn_Risk and S + ADMET_Risk
[see Additional file 6 for chemical structure of FC101a
structural analogs]. Each SA meets Lipinski’s RO5 criteria,
illustrated in Fig. 6. The RO5, a guideline for identifying
drugs with poor absorption and permeation, only ad-
dresses a portion of the gamut of obstacles a compound
must meet to become drugable. In addition to the RO5,
rules independent of MW can accurately predict oral bio-
availability (Veber et al. 2002). Polar surface area (PSA)
and rotatable bond count (nrot) have been found to
accurately differentiate between orally active and non-
orally active drugs (Ghose et al. 1999). Rat oral bio-
availability data from G&G Index of 276 compounds
demonstrates an “accurate and selective criteria” for rat
oral BA > 20-40 % is either nrot ≤ 10 and PSA ≤ 140 Å2 or
Table 4 Comparison of logD at pH 2.5 and 7.4 for FC101a analogs
Analog pH 2.5 Solubility (pH 2.5) pH 7.4 Solubility (pH 7.4)
FC101 Oxazole 2.25 Lipophilic 2.35 Lipophilic
FC101b 1.04 Lipophilic 1.04 Lipophilic
FC101 Imidazole −0.55 Hydrophilic 2.11 Lipophilic
FC101 Formyl −1.3 Hydrophilic 0.75 Lipophilic
FC101N −1.1 Hydrophilic −0.53 Hydrophilic
FC101i −1.78 Hydrophilic 0.17 Lipophilic
FC101L −2.11 Hydrophilic −2.11 Hydrophilic
FC101 Acetonide R −0.66 Hydrophilic 1.67 Lipophilic
FC101 dehydroxyl −0.91 Hydrophilic 0.06 Lipophilic
Kynurenine B −2.27 Hydrophilic −2.2 Hydrophilic
FC101K −1.91 Hydrophilic −0.03 Hydrophilic
FC101a −1.69 Hydrophilic −0.53 Hydrophilic
FC101M −1.02 Hydrophilic −0.76 Hydrophilic
FC101 Phos −1.02 Hydrophilic −0.9 Hydrophilic
Most analogs are hydrophilic, indicating a water-soluble nature. Some analogs like FC101 Oxazole are lipophilic and thus would more readily penetrate the
lipid bilayer
Fig. 8 Predicted aqueous solubility of FC101a and SA. Column graph of predicted aqueous solubility of FC101a hits. All hits display solubility
above Simulations-Plus’ proposed high-risk threshold of 0.01 mg/ml (not shown), suggesting the compounds display solubility similar to orally
bioavailable drugs. FC101a (shaded in blue) and FC101N exhibit the highest degree of solubility and both fall within the slightly soluble range.
Shaded regions indicate solubility based on United States Pharmaceutical (USP) criteria
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number of nrot ≤ 10 and HBD+HBA ≤ 12 (Veber et al.
2002). FC101a and each SA, excluding FC101 Phos, meets
the before mentioned criteria as illustrated in Fig. 7. High
compliance with the RO5 and rules proposed by Veber et
al. (2002) suggests FC101a is likely an orally active com-
pound in humans.
The filter S + Absn_Risk focuses on physiochemical
and biopharmaceutical descriptors. Zhao et al. (2001)
published human intestinal absorption data in relation-
ship to the RO5 and Absn_Risk. Neither filter labels a
drug with experimentally determined fraction absorbed
greater than 50 % as “poorly absorbed.” Moreover,
Absn_Risk picks 50 % more of the poorly absorbed com-
pounds than the RO5. The latter filter, S + ADME-
T_Risk, serves as an all-encompassing filter including 17
weighted rules that access potential liability in relation
to MW, nrot, hydrogen bond donors (HBD), hydrogen
bond acceptors (HBA), PSA, overall formal charge, pre-
dicted logP (S+ logP), effective permeability (Peff ) or ap-
parent permeability (MDCK), aqueous solubility (Sw),
percent of drug unbound to plasma (fup), volume of dis-
tribution (VD), toxicity, and S + Absn_Risk; thereby ac-
cumulating all ranking criteria into a single column.
FC101a scored 0.99 and 1.99, respectively, resulting from
high HBD charge, high steady-state volume of distribu-
tion, and potential mutagenicity (discussed later). In an
effort to eliminate the poorest performing compounds,
we sought to eliminate those analogs performing poorly
for both filters, using a predetermined cut-off point
based on scores from the poorest performing com-
pounds in Simulations-Plus WDI. The focused WDI
comprises a subset of orally bioactive drugs determined
by Simulations-Plus following methods similar to
Lipinski et al. (1997). FC101 Phos exceeds the cut-off for
S + Absn_Risk only; therefore, we were unable to narrow
our drug library (Table 3). FC101a Oxazole is the only
SA scoring 0 for all computational filters and therefore
considered the most optimized SA (Table 3). It is im-
portant to note druglikeness indices (i.e., S + Absn_Risk
and S + ADMET_Risk) are limited in their predictive
power and only estimate the druglikeness of a given
compound, evident by the small portion of focused WDI
compounds that achieved relatively high liability scores
(10 % of WDI scored ≥ 3.5 and > 6.5 for S + Absn_Risk
and S + ADMET_Risk, respectively).
Characterization of the absorption PK profile of
FC101a hits
LogD provides a more meaningful barometer of lipophi-
licity for ionizable compounds; therefore, we used this
parameter to assess the lipophilicity of FC101a, which
has an ionizable 3′ amine group. Hydrophilic molecules
have higher solubility, but are less equipped to readily
cross the cell membrane. Hydrophilicity is represented
by molecules with logD < 0, lipophilicity by molecules
with logD > 0, and excessive lipophilicity by molecules
with logD ≥ 3.5. FC101a and most analogs are of a mod-
est hydrophilic nature at both pH 2.5 and pH 7.4, as
shown in Table 4. All analogs avoid regions of extreme
lipophilicity and extreme hydrophilicity, properties de-
sired in orally bioavailable compounds. FC101a Oxazole
and Imidazole exhibit the highest logD (2.35, 2.11
pH 7.4) and thus are likely less soluble, more permeable,
and more potent than FC101a. Predicted aqueous solu-
bility for FC101a and structural analogs are illustrated in
Fig. 8. ADMET Predictor uses a soft threshold to predict
Fig. 9 Descriptor sensitivity analysis of S+Sw to changes in most
influential descriptors. a Sensitivity of S+SW to changes in number
of amide groups. FC101a includes 0 amide groups, adding this
functionality would increase aqueous solubility. b Sensitivity of S+Sw
to the proximal effect resulting from heteroatoms nitrogen and
oxygen. Lowering the proximity effect below zero would
increase S+Sw
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solubility liability; all hits are predicted to have solubility
higher than the stated minimum threshold. FC101 Oxa-
zole and FC101 Imidazole are the least soluble analogs
(S + Sw = 0.0261 mg/ml and 0.0259 mg/ml, respectively);
FC101N and FC01a are the most soluble compounds
(2.52 mg/ml and 2.34 mg/ml, respectively). One last
means to assess solubility was manually calculating Fsp3.
A study by Lovering et al. (2009) found increasing sp3
hybridized carbon saturation (as measured by Fsp3 = sp3
carbon atoms/total carbon atoms) as drugs progressed
from phase I – market (0.36 for research compounds,
0.47 for marketed drugs); likewise, higher Fsp3 correlated
with higher solubility (Lovering et al. 2009). FC101a
Fsp3 = 0.466, the average value for approved drugs and
drugs with high solubility. Our data found increasing
amide groups and decreasing the proximity effect of het-
eroatoms nitrogen and oxygen would further increase
aqueous solubility of FC101a, illustrated in Fig. 9.
Human jejunal permeability reflects diffusion for pas-
sively transported drugs in the human jejunum- the re-
gion of the intestinal tract with the largest surface area
(Lande et al. 1994; Fagerholm and Lennerniis 1995;
Lennernas et al. 1997). Using a soft threshold for both
apparent and effective permeability models, a four-section
scatter plot was generated, evident in Fig. 10. FC101M
and FC101 Phos fell within region representing low jejunal
and MDCK permeation. Kynurenine B and FC101L fell
within region indicating poor jejunal permeation. All
other analogs, including FC101a, fell within region 2,
which represents high jejunal permeation and no risk of
low MDCK permeation. To further increase jejunal per-
meation of FC101a, Fig. 11 illustrates the effect hydrogen
bond donor protons and intra-molecular hydrogen bonds
have on S + Peff. Many researchers have documented the
importance of hydrogen-bonding capacity in determining
permeability of drug solutes (Waterbeemed and Gifford
2003). Decreasing hydrogen bond protons, perhaps by in-
creasing intra-molecular hydrogen bonds would increase
effective jejunal permeability. Our results are consistent
with data published by Alexander et al. (2011) which
claims intra-molecular hydrogen bonds improves mem-
brane permeability and intestinal absorption (Alexander et
al. 2011).
Characterization of the distribution PK profile of FC101a
hits
A percent of circulating drug may bind to plasma or
whole blood proteins at various affinities, and it is widely
accepted that only unbound drug may interact with
intended molecular targets (Smith et al. 2001). As Fig. 12
shows, FC101a avoids regions of high red blood cell
(RBC) partitioning and regions of extensive plasma pro-
tein binding, with a blood-to-plasma concentration ratio
of 0.97 and 66.61 % unbound to plasma proteins. Ex-
cluding FC101 Phos, each SA avoids regions of both
high RBC partitioning and extensive plasma proteins.
This suggests the compounds are free of RBC metabol-
ism and can efficiently reach the therapeutic target- an
ideal characteristic of an effective drug. In-vitro assays
should be performed to conclude our in-silico findings;
additionally, the appropriate biological fluid must be
chosen when assaying drug concentration in plasma and
whole blood. For drugs with a RBP ≤ 2.0, like FC101a,
measuring concentration in plasma rather than whole
blood or erythrocytes will increase sensitivity to drug
concentration assays (Hinderling 1997). Although it would
be advisable to perform assays with whole blood if
RBC partitioning were pH dependent, our data predicts
Fig. 10 Scatter plot of predicted apparent permeability VS predicted effective permeability. Scatter plot of predicted apparent permeability
(MDCK cm/s × 10^7) VS predicted effective permeability (Peff cm/s × 10^4). Region shaded in red indicates the least desirable permeability
profile. Regions were determined by Simulations-Plus’ proposed high-risk thresholds, and are set at Peff < 0.5 cm/s × 104 and
MDCK < 30 cm/s × 107
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S + PrUnbnd (aka fup) and S + RBP are pH independent
(Hinderling 1997). Therefore in-vitro assays should be
performed on FC101a with plasma as the assay matrix.
Potential neurotherapeutic use of FC101a hits
FC101a has the potential to be developed as a treatment
option for glioblastoma, which are extremely invasive
neurological tumors with both a poor clinical response
and poor prognosis- median survival is 0.4 years
(Mahdavian et al. 2014b; Ohgaki and Kleihues 2005).
FC101a has been shown in previous work to induce
glioblastoma apoptotic cell death and to significantly
reduce the tumor’s migratory capacity (Mahdavian et
al. 2014b). Herein lies the bottleneck: in order for
FC101a to effectively treat glioblastoma, the drug must
efficiently penetrate the BBB. Figure 13 illustrates the
likelihood of penetrating the rat BBB; seven analogs
are classified as probable high BBB penetrators. Two of
the seven, FC101 Formyl (logBB 0.08) and FC101 Acet-
onide R (log BB 0.21), are the most likely candidates to
penetrate the BBB due to their predicted decimal loga-
rithm of blood–brain partition coefficient (logBB),
indicated by the magnitude of the bars in Fig. 13. Al-
though the precise cutoff between high and low BBB
penetration is unknown and different values have been
reported, a log [brain/blood] = −1.0 has been reported
regularly, with larger positive numbers indicating
higher penetration. This suggests FC101 Acetonide R
would be the most likely candidate as a neurotherapeu-
tic agent, although it may require further optimization.
DSA tool found S + logP to be the most influential de-
scriptor to logBB. We suggest structural modifications
designed to increase the logP of FC101 Acetonide R will
thereby increase logBB; specifically, an increase of logP
to 1.0 would result in a logBB of 0.3. Molecules with
logBB > 0.3 tend to readily cross the BBB Vilar et al.
(2010). We provided hints to structural modifications a
medicinal chemist could employ to achieve a higher logP
value. The two most influential descriptors of logP are
formal electric charge and MW, followed by topological
PSA (TPSA). Figure 14 illustrates that lowering formal
electric charge and increasing MW, while reducing
TPSA, would all contribute to an increase in the logP of
FC101a, thus increasing logBB. Increasing MW in order
to increase the probability of BBB penetration may seem
contradictive; it is generally true that smaller molecules
are more likely to penetrate the BBB. Recommendations
similar to the RO5 have been proposed regarding mo-
lecular parameters contributing to a given molecule’s
ability to cross the BBB, i.e., molecules with a molecular
mass < 450 Da are more likely to penetrate the BBB
(Vilar et al. 2010). Therefore we suggest the medicinal
chemist consider the predicted preferred larger MW as a
buffer zone.
Characterization of metabolic and excretion pathways of
FC101a hits
The role of excretion and metabolism significantly
affects the outcome of the drug design process. Under-
standing these pathways aid in predicting drug-drug
interactions (DDI), toxicities, and pharmacokinetics
(Hosey et al. 2014). Kusama et al. (2010) grouped 141
approved drugs by charge and plotted log D, MW, and
fup in three-dimensional space. Clearance pathways
were previously defined for each drug in the dataset,
and were determined to be metabolism by CYP3A4,
Fig. 11 Descriptor sensitivity analysis of S + Peff to changes in most
influential descriptors. a Sensitivity of S + Peff to number of hydrogen
bond donor protons. b Sensitivity of S + Peff to the number of
intra-molecular hydrogen bonds. Adding intra-molecular
hydrogen bonds would lower the number of hydrogen bond
donor protons- this method could be used to increase effective
jejunal permeation
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CYP2C9, CYP2D6, hepatic uptake by OATPs, or un-
changed renal excretion. Boxes were drawn around
each clearance pathway; the mathematical criterion for
drawing the boxes is “maximizing F value (harmonic
mean of precision, and recall) with minimum volume.”
FC101a was plotted as previously described. Figure 15
depicts MW, S + logD, and S + PrUnbnd of FC101a
(red dot) within the defined three-dimensional border
for unchanged renal excretion. Three-dimensional
graph was generated using free software found at: http://
www.bi.cs.titech.ac.jp/CPathPred/pred/rect.html, (Kusama
et al. 2010). Additional file 3 outlines the prediction accur-
acy of each model used within this paper, including logD
(S + logD) and S + PrUnbnd (fup). The external test set
consists of 1,793 logD measurements and 102 fup
measurements, none of which were included in the re-
spective training sets. Both S + logD and S + PrUnbnd
models performed well, with R2 value of 0.8907 and
0.68, respectively [See Additional file 3]. All structures
fell within the AD of each model. It has not escaped
our attention that the previously mentioned classifica-
tion system only examines three members of the cyto-
chrome P450 family, which accounts for 75 % of total
drug metabolism in humans (Guengerich 2008). To
scrutinize our current data, which suggests FC101a is
stable and may clear un-metabolized via the renal sys-
tem; our lab is currently conducting further in-silico
assays and in-vitro microsomal assays to determine if
FC101a interacts with any member of the cytochrome
P450 family.
Fig. 12 Scatter plot of predicted fup VS predicted [blood-to-plasma] ratio. Scatter plot of predicted percent of drug unbound to plasma proteins
VS predicted blood-to-plasma concentration ratio. The shaded regions indicate unfavorable high red blood cell partitioning and extensive plasma
protein binding. For drugs with a RBP > 1.0 suggests partitioning to erythrocytes, indicated by the region shaded red. Drugs with fup≤ 10 %
indicates extensive plasma binding, indicated by the region shaded gray. Industrially accepted
Fig. 13 Assessing capability of FC101a and SA to penetrate BBB. Bar chart depicting logBB values of FC101a hits. Color of bars indicate result
from a binary “High”/”Low” classifier- red bars indicate “High” probability of penetration and black bars indicate “Low” probability of penetration.
The magnitude of each bar indicates the analog’s predicted decimal logarithm of blood–brain partition coefficient. The vertical blue line (−0.1)
indicates a regularly reported cut-off between high and low penetration, with higher penetration having more positive values. The vertical black
bar indicates the cut-off for values that generally easily penetrate the BBB
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Determining potential toxicity of FC101a hits
Animal toxicity issues account for 11 % of total attrition
in drug development, and 20-40 % of drug failures are
attributed to toxicity concerns (Kennedy 1997). There-
fore, we devoted significant attention to determining the
potential toxicity of FC101a. Previous mouse xenograft
studies have shown FC101a to be well-tolerated and
non-toxic at dosages as high as 8 mg/kg/day, which re-
sulted in a 30 % reduction in tumor size (Mahdavian et
al. 2014a). Two prediction models, TOX_Rat and
TOX_BRM_Mouse, determine LD50 for lethal rat acute
toxicity to be 1587.27 mg/kg, and TD50 for tumor induc-
tion in mouse population over a standard lifespan to be
1544.41 mg/kg/day orally, respectively- a near 200 fold
increase in the dose required to reduce tumor size by
30 %.
FC101a was subjected to two over-arching toxicity
prediction models that rank compounds by accumulat-
ing all toxicity related ranking criteria into two columns.
TOX_MUT_Risk is a virtual Ames test summarizing 10
mutagenic models that represent expected mutagenicity
for five strains of Salmonella typhimurium. The second
model, TOX_Risk, takes into account TOX_MUT_Risk
and six other rules focusing on acute toxicity, cardiac
toxicity, carcinogenicity, and hepatotoxicity. Each analog
returned a TOX_Risk score of 0, but only three analogs
returned a 0 score for both filters- FC101 Oxazole,
FC101 Imidazole, and FC101 Phos (see Table 5). FC101
Imidazole and FC101 Phos predicted maximum rec-
ommended therapeutic dose (S + MRTD) is < 3.16 mg/
kg/day, less than 8 mg/kg/day required to reduce
tumor size by 30 % in mouse xenograft models; there-
fore, leaving FC101 Oxazole as the most promising low
toxic SA. From here, we focused on FC101a positive
results (see Table 6). Three strains of S. typhimurium
are potentially sensitive to mutagenic effects of FC101a
and/or its liver metabolites. Our lab plans to validate
results by performing in-vitro Ames Salmonella/micro-
somal assays with all five strains. TOX_ER_filter pre-
dicts FC101a is likely to bind detectably to estrogen
receptor in rats with a relative binding affinity of 48 %
(100 % * (IC50 17βestradiol / IC50 FC101a)). Estrogen
receptor affinity is another area requiring in-vitro as-
sessment in order to decrease the risk of toxicological
late stage failure.
Fig. 14 Descriptor sensitivity analysis of logP in response to three
most influential descriptors. All three graphs chart the sensitivity of
S + logP to a unique descriptor. a Response of model to TPSA.
Lowering the topological polar surface area of FC101a to
approximately 100 would increase S + logP to1.0. b Response of
model to formal electric charge. FC101a charge is 0, slightly
lowering this charge would increase S + logP. c Response of model
to molecular weight. Increasing MW would raise S + logP
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Transporter protein P-gp can mediate toxic DDIs
(Hosey et al. 2014), largely due to its wide substrate
spectrum overlap with CYP3A4 (Finch and Pillans
2014). For example, rosuvastatin uptake is inhibited by
cyclosporine and results in a sevenfold increase in AUC,
potentially leading to serious side effects (Simonson et
al. 2004). ADMET Predictor’s S + Pgp_Substrate model
was used to predict the likelihood of P-gp efflux. FC101a
was classified as a non-substrate with a 97 % likelihood
of no P-gp efflux, lowering the perceived risk of P-gp
mediated DDIs.
Drugs with low target specificity often bind to multiple
sites, thereby increasing the required minimum dose and
the probability of unwanted side effects. Figure 16 illus-
trates a specificity matrix containing docking scores be-
tween eleven biological targets, respective FDA approved
drugs, and FC101a. High affinity binding should only
occur along a diagonal line that represents affinity
between each target and its respective drug. For drugs
expressing high target specificity, the cells are highlighted
in gray; cells highlighted in blue indicate high affinity
binding to a non-target, indicating low specificity. FC101a
binds weakly to each of the eleven targets, a characteristic
of highly specific molecules with low toxicity. A more
complete computational strategy for addressing specificity
would involve virtually docking FC101a with all potential
targets within a cell; however, a complete database for this
approach is currently non-existent. Our method of using
targets that span all known classes of therapeutic targets is
the beginning for others to build such a database (Shaikh
et al. 2007). To increase the accuracy of future models, we
will choose multiple sets of 11 random targets, each from
a class of known therapeutic targets.
Potential anti-cancer mechanisms of action
We performed 49 molecular dockings between unam-
biguous protein structures involved in caspase mediated
extrinsic apoptosis and FC101a, FC101b, and kynure-
nine. Table 7 depicts docking scores with FC101a. PDB ID
2K7Z (Total Score 8.7926), which represents the mono-
meric unprocessed catalytic domain of the caspase-8
zymogen (procaspase-8); and PDB ID 3H11 (Total Score
Fig. 15 Three-dimensional graph depicting possible FC101a clearance pathway. Three-dimensional graph depicts FC101a clearance pathway (red
dot) in relation to boundaries of three clinically significant clearance pathways- pathways were determined by Kusama et al. (2010). Red box
indicates cluster of drugs undergoing renal clearance, green box indicates cluster of drugs undergoing CYP3A4 metabolism, and purple box
indicates cluster of drugs undergoing CYP2D6 metabolism. Graph was generated at: http://www.bi.cs.titech.ac.jp/CPathPred/pred/rect.html
Table 5 Overall toxicity predictions for FC101a using
TOX_MUT_Risk and TOX_Risk filters
Analog TOX_MUT_Risk TOX_Risk
FC101 Oxazole 0 0
FC101b 1 0
FC101 Imidazole 0 0




FC101 Acetonide R 1 0
FC101 dehyroxyl 1 0




FC101 Phos 0 0
Filters provide a qualitative estimate of potential toxicity concerns. Approximately
16 % of commercial drugs within the focused subset of the WDI receive a
TOX_MUT_Risk score > 1 and approximately 4 % have a score > 2. TOX_Risk
evaluates overall toxicological concerns and is greater than 3.3 for ~10 % of the
focused WDI
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8.6323), the crystal structure of the protease-like domain
of cellular FLICE- inhibitory protein (cFLIP(L)) in com-
plex with procaspase-8 are the top two ranked proteins
with the highest affinity for FC101a are (see Fig. 17). We
propose a mechanism of action by which binding of
FC101a to either or perhaps both the protease-like do-
main of cFLIP(L) and procaspase-8, as shown in Fig. 17,
could enhance heterodimerization between the two mole-
cules, thus enhancing caspase activity and leading to
apoptosis upregulation. Our proposed mechanisms are
based on four observations; substantial levels of cFLIP
have been recorded in human cancers such as ovarian,
colon, glioblastoma, breast, colorectal, and prostate, and it
has been recognized as a major regulator of apoptosis,
utilizing dual functionality- cFLIP(L) inhibits caspase-8 ac-
tivation at high expression levels, but increases caspase-8
activity at low levels (Safa et al. 2008; Bagnoli et al. 2010);
prior to caspase-induced apoptosis induction, procaspase-
8 must be recruited to FADD and form the DISC,
followed by caspase heterodimerization and proteolytic
cleavage; cFLIP(L) is capable of increasing the proteolytic
activity of caspase-8 by facilitating heterodimerization of
the two molecules, yet the mechanism forcing these two
molecules together and thereby leading to enhanced
initiator caspase activation remains unclear (Yu et al.
2009); and finally, FC101a interacts with regions from
both chain A and chain B of the caspase-8: cFLIP com-
plex, illustrated in Fig. 18, and docking with either chain
independent of the other resulted in scores below the
minimum allowed threshold. Our logic is in-line with the
notion proposed by others that drugs targeting caspase-8
isoforms and c-FLIP variants may offer a therapeutic ad-
vantage (Safa et al. 2008). Nonetheless, in-vitro analysis
must be performed in future studies to confirm or elimin-
ate our proposed mechanisms.
Conclusion
FC101a demonstrates tremendous potency towards mul-
tiple cancer cell lines, yet exhibits modest in-vivo anti-
cancer activity. Potential therapeutic compounds are
useless without having a desirable PK profile, and thus it
is vital to find the source of such diminished potency if
one wishes to develop a marketable drug. In addition to
investigating the novel mode of action of FC101a, this
study was designed, in-part, to answer two questions
utilizing primarily in-silico techniques: why is in-vivo
potency diminished, and how can we improve in-vivo
potency? Objectively, we aimed to characterize the
Table 6 Positive toxicity model prediction results for FC101a
Toxicity model Output Model definition
TOX_ER_filter Toxic (48 %) Qualitative assessment of estrogen receptor toxicity in rats.
TOX_MUT_97 + 1537 Positive Qualitative assessment of mutagenicity of the pure compound in TA97 and/or
TA1537 strains of S. typhimurium.
TOX_MUT_m97 + 1537 Positive Qualitative assessment of mutagenicity of the compound and its microsomal rat
liver metabolites in TA97 and/or TA1537 strains of S. typhimurium.
TOX_MUT_m98 Positive Qualitative assessment of mutagenicity of the compound and its microsomal rat
liver metabolites in TA98 strain of S. typhimurium.
Of 20 applicable toxicity prediction models, four returned positive results
Fig. 16 In-silico specificity matrix based on eleven randomly chosen FDA approved drugs. Two-dimensional specificity matrix generated in-silico.
Matrix was generated using binding affinity scores calculated from SYBYL-X Total Score- a robust scoring function. The gray diagonal line indicates
binding between drugs and their therapeutic target- high binding scores should only occur along the diagonal line, if drugs are highly specific
for their intended therapeutic target. Docking scores with FC101a (green row) do not exceed any scores along the gray line, possibly indicating
that FC101a is specific for its unknown target(s). Four of the eleven drugs bind strongly to at least one non-target, indicative of low target
specificity (red cells). Drugs 2, 3, 6, and 8–11 are specific to their respective targets
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ADMET profile of FC101a, to determine those structural
analogs with the most promising ADMET profile, to
suggest methods of PK optimization, and to elucidate
potential biological targets of FC101a.
We verified FC101a compliance with both Lipinski’s
RO5 for orally bioavailable drugs and with Veber’s
selective criteria for rat oral bioavailability > 20-40 %.
We analyzed each ADMET component of FC101a to
identify molecular properties and descriptors contribut-
ing to a successful PK profile, and properties requiring
optimization. The most relevant computed ADMET
descriptors and values are displayed in Table 8 for
both FC101a and those structural analogs selected for
synthesis and anti-cancer potency assessment. Addition-
ally, FC101 Phos was included for comparison, given its
least desirable performance. Recommended range of
values for i) 95 % of orally bioavailable drugs or ii) conser-
vative threshold to risk determined by ADMET Predictor
Version 7.1 were included for each value. We accumulated
more evidence suggesting FC101a possesses high potential
for drug development. Furthermore, we identified FC101
Oxazole (preferred due to lower predicted MRTD) and
FC101 Imidazole as the most optimized analogs, and
given their higher lipophilic logD, it is possible potency
could be increased thereby addressing FC101a’s modest
in-vivo activity. We were unable to eliminate any com-
pound from our group of analogs based S + Absn_Risk
and S + ADMET_Risk scores, although FC101 Phos per-
formed the worst. We found FC101a to have low risk
scores from four physiochemical and biopharmaceutical
filters, compliance with the RO5 and Veber’s druglike in-
dices, desirable predicted aqueous solubility (logS, S + Sw,
Fsp3, and hydrophobic logD), logP, effective and apparent
permeation values, possible un-metabolized clearance via
the renal system, high target specificity, and no affinity for
P-gp. Additionally we identified FC101 Formyl and FC101
Acetonide R as the analogs most likely to penetrate the
BBB. Secondly, and perhaps most important, we identified
Table 7 Molecular docking affinity scores between FC101a and
potential biological targets
























Proteins are ranked in descending order. *Chain B was removed during
preparation. **Chains A, B, and D were removed during preparation Fig. 17 FC101a docked into two highest scoring proteins.
a Three-dimensional rendering of FC101a bound to binding site
in top ranked protein, procaspase-8 (PDB 2K7Z). b FC101a clearly
interacting with regions from both chain A (green) and chain B
(red) of the Caspase-8: cFLIP complex
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Fig. 18 Two-dimensional rendering of FC101a bound to procaspase-8 – cFLIP(L) complex. Dash red lines indicate interactions between FC101a and both
proteins from PDB ID 3H11. More specifically FC101a interacts with i) oxygen of His334, two oxygen atoms of side chain carboxyl group of GLU398,
hydrogen atom of side chain nitrogen from ARG337 of chain A, and ii) two hydrogen atoms of side chain amide nitrogen from ASN393 of chain B
Table 8 Important computed ADMET properties and their recommended ranges for orally active drugs
Property Description Recommended range FC101a FC101 Oxazole FC101 Imidazole FC101 Phos
MW Molecular weight in Da <450 292.34 300.32 299.33 372.32
PSA Surface sum of all polar atoms and attached
atoms in Å2
<140 110.708 89.708 94.106 167.62
Nrot Number of rotatable bonds <10 4 3 3 6
HBD Number of hydrogen bond donors <5 3a 1 2 4
HBA Number of hydrogen bond acceptors ≤8 6 6 6 9
LogP Octanol-water partition coefficient ≤4.5 0.89 2.35 2.14 −0.91
LogD Octanol-water distribution coefficient ≤3.5 −0.53 2.35 2.11 −0.9
Sw Aqueous solubility in mg/ml ≥0.010 2.34 0.0261 0.0259 0.7740
LogS Log of aqueous solubility −6.0 – 0.5 −3.39 −4.29 −3.66 −1.81
MDCK Apparent Madin-Darby canine kidney cell
permeability in cm/s × 107
≥30 44.79a 313.79 212.86 14.82
Peff Human effective jejunal permeation in
cm/s × 104
≥0.5 0.75a 3.29 2.36 0.29
Fsp3 Fraction of sp3 C to total C atoms >0.36 0.467 0.313 0.313 0.467
RBP Blood-to-plasma concentration ratio <1.0 0.97a 0.81 0.85 0.62
Vd Volume of distribution in L/kg ≤3.7 6.7 2.76 3.82 0.6
Fup Percent of drug unbound to plasma proteins >10 % 66.61 13.1 15.35 36.48
MolVol Molal volume at normal boiling point in cm3/mol <475 308 294 301 364
hERG pIC50 as measure of affinity for hERG K+ channel ≤5.5 4.51 4.24 4.53 3.76
MRTD Maximum recommended therapeutic dose in
mg/kg/day
>3.16 >3.16 >3.16 <3.16 <3.16
TOX Risk summary for mutagenic potential in
S. typhimurium
≤1 1a 0 0 0
MUT
Risk
Absn_Risk Risk summary for oral absorption <3.5 0.99 0 0 3.5
ADMET_Risk Summary of all predicted ADMET risk factors ≤6.5 1.99 0 0.06 3.5
Recommended ranges are determined by range of 95 % of orally bioactive drugs and/or cut-offs pre-determined by ADMET Predictor Version 2.0, as defined
below. Seven of the cut-offs are within the range of 95 % of orally bioactive drugs. Molar weight (range for 95 % of drugs: 130–725 Da); LogP (range for 95 % of
drugs: −2 to 6.5); HBA (range for 95 % of drugs: 2–20); HBD (range for 95 % of drugs: 0–6); nrot (range for 95 % of drugs: 0–15); MDCK permeability in nm/s (range
for 95 % of drugs: < 5 low, > 500 high); LogS (range for 95 % of drugs: −6.0 to 0.5) (Ntie-Kang et al. 2013); TOX_MUT_Risk, Absn_Risk, ADMET_Risk, Sw, Peff, MDCK,
MW, Mol Vol, LogD, Vd, Fup, and hERG pIC50 exact cut-offs pre-determined by ADMET Predictor. (ADMET Predictor V2 Manual); PSA (<140 based on Veber et al.
(2002)); Fsp3 range based on Lovering et al. (2009). Bolded values indicate values outside the range of 95 % of orally bioactive drugs and/or exceeding risk cut-off.
aValues indicate properties likely needing optimization or in-vitro assessment
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areas of concern. These areas of concern require further
in-vitro testing and include:
 FC101a potential mutagenic affects on S.
typhimurium strains TA97, TA1537, and TA98.
 FC101a potential estrogen receptor toxicity,
although the ratio binding percent was relatively
low.
Areas of likely needed optimization include:
 Hydrogen bond donor charge
 Apparent and effective permeability
 Blood-to-plasma concentration ratio
 Volume of distribution
Our third objective was to discover potential avenues
medicinal chemists could use to optimize FC101a;
therefore, we analyzed each ADMET component of
FC101a to identify properties with the potential for
modification. Subsequently, we hinted at avenues by
which a medicinal chemist could optimize effective per-
meation, BBB penetration, and aqueous solubility. The
means of accomplishing these changes is beyond the
scope of this paper, and is of course an oversimplifica-
tion. Structure based differences play a major role in
oral bioavailability and it is not surprising that difficul-
ties are encountered during the optimization of drugs.
Nonetheless, our data provides medicinal chemists hints
for structural modifications that could achieve more
desirable PK features. Diminished in-vivo activity can
now be addressed and scientists can begin to further
understand the mechanisms behind such behavior. In-
silico data should be followed up with in-vitro assays,
and currently our lab is in the process of doing so.
In order to investigate the mechanism of action for
FC101a, our fourth objective, we designed a docking
protocol to elucidate possible biological targets. A con-
sensus scoring function and protocol was designed by
docking hKAT II with its known biological substrate,
kynurenine – a naturally occurring metabolite sharing
structural similarities with FC101a. The protocol was
applied to 49 proteins involved in caspase-mediated
apoptosis. Docking results led to proposing three similar
mechanisms of action by which FC101a facilitates hetero-
dimerization of procaspase-8 by targeting either or both
procaspase-8 and cFLIP(L), strengthening the affinity be-
tween the two molecules and thus enhancing extrinsic
apoptosis. Investigating these potential targets warrant
further in-vitro assessment.
Future FC101a research efforts should focus on dis-
covery of new potential targets involved in apoptosis
promoting pathways, assessment of proposed biological
target(s), in-vitro validation of in-silico results presented
within (i.e., Ames test, microsomal assays, drug concen-
tration in plasma), and enhancing in-vivo potency via PK
optimization. Additionally, researchers interested in de-
veloping a potentially potent treatment for glioblastoma
tumors should focus on optimizing FC101 Formyl and
FC101 Acetonide R to penetrate the BBB; although,
these analogs should first be assessed for anti-cancer
activity. In conclusion, FC101a’s high specificity and
promising ADMET profile, along with its documented
potent anti-cancer activity, render this molecule a prom-
ising lead candidate for a low toxic anti-cancer agent ef-
fective against a broad range of cancers. FC101a should
continue to be developed and prepared for translational
drug studies; first generation structural analogs, FC101
Oxazole and FC101 Imidazole, should be explored as
lead candidates.
Additional files
Additional file 1: ADMET Predictor clean output file. Contains all
predicted descriptors, parameter settings, and out-of-scope indicator
column.
Additional file 2: Original 2D SDF file used to generate ADMET
values. The file contains more than 14 structures, despite only 14 being
covered in this original manuscript. Some structures are enantiomers,
which are unrecognizable by ADMET Predictor Version 7.1.
Additional file 3: Statistical measurement of binary and linear
predictive models in order to estimate prediction accuracy of
ADMET Predictor. Contains concordance, sensitivity, and specificity of all
binary models used in this study; contains R2 values and n for both
training and test sets for all models used in this study.
Additional file 4: Detailed account of molecular docking protocol
for caspase-related proteins. Detailed account of the steps, protocol,
and settings used to dock leadset4 with all 49 proteins of interest. Details
are of most significance to the SYBYL-X user.
Additional file 5: Specificity matrix design and SYBYL-X molecular
docking detailed protocol. Detailed experimental section for the
retrieval, preparation, and molecular docking of 11 FDA approved drugs
with their therapeutic target. Data used to design specificity matrix and
to investigate FC101a’s specificity. Details are of the most significance to
the SYBYL-X user.
Additional file 6: Chemical structure of FC101a structural analogs.
Chemical structure and short description of the altered functionality of
each compound.
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and observed values for an output. The network consists of inputs,
neurons, and an output; BA: Bioavailability; S+ logD: Octanol-water
distribution coefficient; S+ Sw: Aqueous water solubility in mg/ml;
S+ Peff-: Effective permeability in the human jejunal; S+ MDCK: Apparent
Madin Darby Canine Kidney COS permeability; S+ PrUnbnd: Percent of
drug unbound to plasma proteins, aka Fup; S+ RBP: Blood-to-Plasma
concentration ratio; S+ logBB: Logarithm of the blood–brain partition
coefficient; MW: Molecular weight; P-gp: Permeability-Glycoprotein;
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DSA: Descriptor sensitivity analysis tool by ADMET Predictor;
AD: Applicability domain refers to the region of molecular descriptor space
occupied by all the drugs used to train a prediction model; hKAT-II: Human
Kynurenine Aminotransferase II; Threshold: One of the two parameters
determining the extent of the protomol. This factor (between 0.01 and
0.99) indicates how much the protomol can be buried in the protein. The
default of 0.50 is adequate in most circumstances. Increasing this number
will decrease the volume; Bloat: This second parameter provides a way to
inflate the protomol. Use the slider to specify the number of Å (0–10) used
to expand the protomol in 3D. Changing this parameter may affect the
protomol’s volume in the following situations: 1) With a longer distance,
the protomol can reach into crevices. 2) If the active site is a channel,
rather than a cavity, longer distances may be required to better define the
protomol at the open ends of the channel; MCS mode: Multi-Channel
Surface mode; Total Score: An empirically derived scoring function that is
based on the binding affinities of protein-ligand complexes and on their
X-ray structures. Expressed as –log(kd); C Score: Consensus scoring
function. It is the simultaneous use of multiple different scoring functions
in order to make more accurate predictions; nrot: Rotatable bond count;
HBD: Hydrogen bond donor; HBA: Hydrogen bond acceptor; PSA: Polar
surface area in angstroms squared; S+ logP: Octanol-water partition
coefficient; VD: Volume of distribution; RBC: Red blood cell partitioning;
TPSA: Topological Polar Surface Area in Angstroms squared; DI: Drug-drug
interaction(s); UC: Area under curve, aka integral, is plot of drug
concentration in blood plasma against time; ADD: Fas-Associated protein
with death domain; ISC: Death-inducing signaling complex.
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